Successful Pre- and Post-transplant Administration of Gilteritinib in a Patient with Relapsed and Refractory Acute Myeloid Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

• Published in: Internal Medicine Vol. 62; no. 15; pp. 2243 - 2247
• Main Authors: Edahiro, Taro, Ureshino, Hiroshi, Chishaki, Ren, Fujino, Keita, Mino, Tatsuji, Yoshida, Tetsumi, Fukushima, Noriyasu, Ichinohe, Tatsuo
• Format: Journal Article
• Language: English
• Published: Japan The Japanese Society of Internal Medicine 01.08.2023; Japan Science and Technology Agency
• Subjects: Acute myeloid leukemia; allogenic stem cell transplantation; Allografts; Bone marrow transplantation; Case Report; FLT3 mutation; Flt3 protein; gilteritinib; graft-versus-host disease; Graft-versus-host reaction; graft-versus-leukemia effect; Hematopoietic stem cells; Internal medicine; Mutation; Patients; Peripheral blood; Protein-tyrosine kinase; Stem cell transplantation; allogenic stem cell transplantation; gilteritinib; acute myeloid leukemia; graft-versus-host disease; FLT3 mutation; graft-versus-leukemia effect
• ISSN: 0918-2918; 1349-7235
• DOI: 10.2169/internalmedicine.1069-22

Patients with acute myeloid leukemia (AML) harboring FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication mutation are associated with a poor survival outcome, even those receiving allogeneic stem cell transplantation (Allo-SCT). An additional treatment strategy with allo-SCT is therefore required to reduce relapse in these patients. Gilteritinib is a specific FLT3 inhibitor that has shown clinical benefit for patients with relapsed and refractory (R/R) AML harboring FLT3 mutation. We herein report a 49-year-old woman with R/R AML who was successfully treated with pre- and post-transplant gilteritinib. Post-transplant gilteritnib yielded a durable response with possible exacerbation of graft-versus-host disease.